Korro Bio击败了Q3收入估计数,但尽管收入强劲,治疗工作取得积极进展,股票却下跌。 Korro Bio beat Q3 earnings estimates but saw stock drop despite strong revenue and positive therapy progress.

Korro Bio(KRRO)报告的收入比预期的Q3好,每股损失1.92美元,粗略估计数为69美元,收入为109万美元,远远超过预测的410 000美元。 Korro Bio (KRRO) reported better-than-expected Q3 earnings with a loss of $1.92 per share, beating estimates by $0.69, and revenue of $1.09 million, far exceeding the $410,000 forecast. 尽管股票表现强, 但周四股价下跌0.43美元至6.07美元, Despite strong results, the stock fell $0.43 to $6.07 on Thursday, with volume more than double average. 该公司正在开发一种针对α-1抗素缺乏症的RNA编辑疗法,目前拥有共识"持有"评级,平均价格目标为76.00美元,因为多家公司将其评级降级为"市场表现"或"部门表现". The company, developing an RNA-editing therapy for Alpha-1 Antitrypsin Deficiency, now holds a consensus "Hold" rating and an average price target of $76.00, as multiple firms downgraded its rating to "Market Perform" or "Sector Perform." 分析员预测全年每股损失9.52美元。 Analysts project a full-year loss of $9.52 per share.